Euglycemic ketoacidosis complicating empagliflozin therapy in a Bangladeshi type 2 diabetic lady
Abstract
Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, which may occurin both type 1 and type 2 diabetic patients. It is characterized by hyperglycaemia [blood glucose levels > 250 mg/dL (13.8 mmol/ L)], metabolic acidosis (pH <7.3 or serum bicarbonate <15 mmol/L) with an increased anion gap and the presence of ketone bodies in blood or urine. A subgroup of patients may present without signs of hyperglycemia, rather present with euglycemia, posing a diagnostic challenge due to the absence of the cardinal findings of the pathophysiology in DKA. Here, we report a case of euglycemic ketoacidosis complicating a 50-year-old Bangladeshi diabetic lady receiving empagliflozin treatment.
BIRDEM Med J 2021; 11(3): 243-245
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.